Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	molecular adaptor activity	ARID1B KMT2D MIDN SHANK2 BCORL1 AMBRA1 RCOR3 IRS2 SCRIB EP300 RXRB CRK SOS1	2.58e-05	1356	51	13	GO:0060090
GeneOntologyMolecularFunction	kinase binding	MLXIPL MIDN NBEAL2 BRSK2 PER1 IRS2 SCRIB MAPK7 BRSK1 EP300 CRK	2.65e-05	969	51	11	GO:0019900
GeneOntologyMolecularFunction	protein-macromolecule adaptor activity	ARID1B KMT2D SHANK2 BCORL1 AMBRA1 RCOR3 IRS2 SCRIB EP300 RXRB CRK SOS1	2.68e-05	1160	51	12	GO:0030674
GeneOntologyMolecularFunction	structural constituent of synapse	SHANK2 PCLO BSN	1.68e-04	42	51	3	GO:0098918
GeneOntologyMolecularFunction	structural constituent of presynaptic active zone	PCLO BSN	1.77e-04	8	51	2	GO:0098882
GeneOntologyMolecularFunction	tau protein binding	BRSK2 BRSK1 EP300	2.21e-04	46	51	3	GO:0048156
GeneOntologyMolecularFunction	protein kinase binding	MLXIPL NBEAL2 BRSK2 IRS2 SCRIB MAPK7 BRSK1 EP300 CRK	3.26e-04	873	51	9	GO:0019901
GeneOntologyMolecularFunction	signaling adaptor activity	SHANK2 IRS2 SCRIB CRK	3.28e-04	129	51	4	GO:0035591
GeneOntologyMolecularFunction	signaling receptor complex adaptor activity	SHANK2 IRS2 CRK	3.55e-04	54	51	3	GO:0030159
GeneOntologyMolecularFunction	transcription coregulator binding	PCLO PER1 BSN EP300	4.48e-04	140	51	4	GO:0001221
GeneOntologyMolecularFunction	transcription corepressor binding	PCLO PER1 BSN	4.61e-04	59	51	3	GO:0001222
GeneOntologyMolecularFunction	SH3 domain binding	SHANK2 CCDC6 CRK SOS1	4.85e-04	143	51	4	GO:0017124
GeneOntologyMolecularFunction	protein antigen binding	EP400 EP300	7.50e-04	16	51	2	GO:1990405
GeneOntologyMolecularFunction	tau-protein kinase activity	BRSK2 BRSK1	1.43e-03	22	51	2	GO:0050321
GeneOntologyMolecularFunction	chromatin binding	ARID1B SFPQ EP400 PER1 ARID3C EP300 RXRB	2.59e-03	739	51	7	GO:0003682
GeneOntologyMolecularFunction	transcription coregulator activity	ARID1B KMT2D BCORL1 RCOR3 EP300 RXRB	2.98e-03	562	51	6	GO:0003712
GeneOntologyMolecularFunction	mitogen-activated protein kinase binding	MAPK7 EP300	3.61e-03	35	51	2	GO:0051019
GeneOntologyMolecularFunction	magnesium ion binding	TREX1 BRSK2 BRSK1 MAST2	3.62e-03	247	51	4	GO:0000287
GeneOntologyMolecularFunction	phosphatase binding	AMBRA1 PPP1R11 IRS2 MAST2	4.58e-03	264	51	4	GO:0019902
GeneOntologyBiologicalProcess	synaptic vesicle clustering	PCLO BRSK2 BRSK1 BSN	2.16e-07	22	50	4	GO:0097091
GeneOntologyBiologicalProcess	microtubule cytoskeleton organization involved in establishment of planar polarity	BRSK2 BRSK1	1.73e-05	3	50	2	GO:0090176
GeneOntologyBiologicalProcess	presynapse to nucleus signaling pathway	PCLO BSN	1.73e-05	3	50	2	GO:0099526
GeneOntologyBiologicalProcess	synaptic vesicle localization	PCLO BRSK2 BRSK1 BSN	2.63e-05	71	50	4	GO:0097479
GeneOntologyBiologicalProcess	presynaptic signal transduction	PCLO BSN	3.44e-05	4	50	2	GO:0098928
GeneOntologyBiologicalProcess	synaptic vesicle targeting	PCLO SCRIB	5.73e-05	5	50	2	GO:0016080
GeneOntologyBiologicalProcess	presynaptic active zone assembly	PCLO BSN	5.73e-05	5	50	2	GO:1904071
GeneOntologyBiologicalProcess	maintenance of presynaptic active zone structure	PCLO BSN	8.59e-05	6	50	2	GO:0048790
GeneOntologyBiologicalProcess	maintenance of synapse structure	SHANK2 PCLO BSN	1.24e-04	40	50	3	GO:0099558
GeneOntologyBiologicalProcess	regulation of carbohydrate metabolic process	MLXIPL TREX1 MIDN IRS2 EP300	2.37e-04	231	50	5	GO:0006109
GeneOntologyBiologicalProcess	presynaptic active zone organization	PCLO BSN	2.56e-04	10	50	2	GO:1990709
GeneOntologyBiologicalProcess	response to reactive oxygen species	TREX1 MAPK7 MMP9 EP300 CRK	3.17e-04	246	50	5	GO:0000302
GeneOntologyBiologicalProcess	vesicle localization	PCLO BRSK2 SCRIB BRSK1 BSN	3.23e-04	247	50	5	GO:0051648
GeneOntologyBiologicalProcess	cellular response to hormone stimulus	ARID1B KMT2D PER1 IRS2 EP300 RXRB CRK SOS1	3.32e-04	727	50	8	GO:0032870
GeneOntologyBiologicalProcess	regulation of synaptic vesicle clustering	BRSK2 BRSK1	3.74e-04	12	50	2	GO:2000807
GeneOntologyBiologicalProcess	establishment or maintenance of cell polarity	BRSK2 SCRIB ARHGAP35 BRSK1 CRK	3.87e-04	257	50	5	GO:0007163
GeneOntologyBiologicalProcess	synaptic vesicle cycle	PCLO BRSK2 SCRIB BRSK1 BSN	4.38e-04	264	50	5	GO:0099504
GeneOntologyBiologicalProcess	regulation of nucleotide catabolic process	MLXIPL TREX1 EP300	4.80e-04	63	50	3	GO:0030811
GeneOntologyBiologicalProcess	regulation of purine nucleotide catabolic process	MLXIPL TREX1 EP300	4.80e-04	63	50	3	GO:0033121
GeneOntologyBiologicalProcess	regulation of glycolytic process	MLXIPL TREX1 EP300	4.80e-04	63	50	3	GO:0006110
GeneOntologyBiologicalProcess	cell junction maintenance	SHANK2 PCLO BSN	5.27e-04	65	50	3	GO:0034331
GeneOntologyBiologicalProcess	steroid hormone receptor signaling pathway	KMT2D PER1 EP300 RXRB	5.40e-04	155	50	4	GO:0043401
GeneOntologyBiologicalProcess	cellular response to oxygen-containing compound	MLXIPL TREX1 ARID1B BRSK2 IRS2 MAPK7 MMP9 EP300 RXRB CRK SOS1	5.81e-04	1450	50	11	GO:1901701
GeneOntologyCellularComponent	cytoskeleton of presynaptic active zone	PCLO BSN	1.56e-04	8	50	2	GO:0048788
GeneOntologyCellularComponent	presynaptic active zone	SHANK2 PCLO BRSK1 BSN	3.59e-04	141	50	4	GO:0048786
GeneOntologyCellularComponent	presynaptic cytoskeleton	PCLO BSN	5.01e-04	14	50	2	GO:0099569
HumanPheno	Abnormal morphology of the radius	MLXIPL ARID1B BICRA MMP9 EP300 SOS1	3.12e-05	217	16	6	HP:0002818
HumanPheno	Abnormal forearm bone morphology	MLXIPL ARID1B BICRA MMP9 EP300 SOS1	5.02e-05	236	16	6	HP:0040072
HumanPheno	Abnormal forearm morphology	MLXIPL ARID1B BICRA MMP9 EP300 SOS1	5.40e-05	239	16	6	HP:0002973
HumanPheno	Disordered formal thought process	MLXIPL TREX1 ARID1B BICRA BCORL1 RFX7 EP300	8.53e-05	386	16	7	HP:0025769
HumanPheno	Abnormal cheek morphology	MLXIPL ARID1B KMT2D BICRA PCLO EP300	1.36e-04	282	16	6	HP:0004426
HumanPheno	Abnormality of the helix	KMT2D BICRA KIAA0586 EP300 SOS1	1.79e-04	183	16	5	HP:0000380
HumanPheno	Large earlobe	MLXIPL KMT2D BICRA	1.85e-04	37	16	3	HP:0009748
HumanPheno	Abnormal size of the palpebral fissures	MLXIPL KMT2D BICRA PCLO RFX7 EP300	1.85e-04	298	16	6	HP:0200007
HumanPheno	Depressed nasal bridge	MLXIPL ARID1B KMT2D BICRA PCLO KIAA0586 EP300 SOS1	2.21e-04	612	16	8	HP:0005280
HumanPheno	Flattened nasal bridge	MLXIPL ARID1B KMT2D BICRA PCLO KIAA0586 EP300 SOS1	2.21e-04	612	16	8	HP:0000425
HumanPheno	Epicanthus	MLXIPL ARID1B KMT2D BICRA KIAA0586 RFX7 EP300 SOS1	2.26e-04	614	16	8	HP:0000286
HumanPheno	Pneumonia	TREX1 ARID1B KMT2D KIAA0586 RFX7 EP300	2.34e-04	311	16	6	HP:0002090
HumanPheno	Chiari malformation	MLXIPL KMT2D BICRA EP300	2.76e-04	107	16	4	HP:0002308
HumanPheno	Abnormal femoral neck/head morphology	TREX1 ARID1B KIAA0586 MMP9 EP300	2.79e-04	201	16	5	HP:0003366
HumanPheno	Posteriorly rotated ears	ARID1B KMT2D BICRA KIAA0586 RFX7 EP300 SOS1	2.97e-04	470	16	7	HP:0000358
HumanPheno	Pilomatrixoma	KMT2D EP300	3.29e-04	9	16	2	HP:0030434
HumanPheno	Prominent fingertip pads	ARID1B KMT2D EP300	3.56e-04	46	16	3	HP:0001212
HumanPheno	Abnormal helix morphology	KMT2D BICRA KIAA0586 EP300 SOS1	3.57e-04	212	16	5	HP:0011039
HumanPheno	Abnormal upper limb bone morphology	MLXIPL ARID1B BICRA KIAA0586 MMP9 EP300 SOS1	3.57e-04	484	16	7	HP:0040070
HumanPheno	Cerebellar malformation	MLXIPL ARID1B KMT2D BICRA KIAA0586 RFX7 EP300	3.71e-04	487	16	7	HP:0002438
HumanPheno	Abnormality of the larynx	MLXIPL TREX1 ARID1B KMT2D PODXL DLST RFX7 EP300	4.01e-04	666	16	8	HP:0001600
HumanPheno	Chiari type I malformation	MLXIPL KMT2D EP300	4.04e-04	48	16	3	HP:0007099
HumanPheno	Prominent digit pad	ARID1B KMT2D EP300	4.04e-04	48	16	3	HP:0011298
HumanPheno	Abnormality of the palpebral fissures	MLXIPL ARID1B KMT2D BICRA PCLO BCORL1 RFX7 EP300 SOS1	4.73e-04	880	16	9	HP:0008050
HumanPheno	Long eyelashes	ARID1B KMT2D BICRA EP300	5.64e-04	129	16	4	HP:0000527
HumanPheno	Restricted or repetitive behaviors or interests	MLXIPL ARID1B BICRA BCORL1 RFX7 EP300	5.86e-04	368	16	6	HP:0031432
HumanPheno	Abnormal midface morphology	MLXIPL ARID1B KMT2D BICRA PCLO RFX7 EP300 SOS1	5.90e-04	704	16	8	HP:0000309
HumanPheno	Duodenal ulcer	ARID1B EP300	5.99e-04	12	16	2	HP:0002588
HumanPheno	Hypoplasia of the phalanges of the toes	ARID1B EP300	5.99e-04	12	16	2	HP:0010746
HumanPheno	Panic attack	PODXL DLST EP300	6.04e-04	55	16	3	HP:0025269
HumanPheno	Abnormality of calvarial morphology	TREX1 ARID1B KMT2D BICRA PCLO KIAA0586 BCORL1 RFX7 EP300 SOS1	6.08e-04	1134	16	10	HP:0002648
HumanPheno	Non-epileptic seizure	PODXL DLST EP300	6.37e-04	56	16	3	HP:0033052
HumanPheno	Low hanging columella	KMT2D BICRA EP300	6.37e-04	56	16	3	HP:0009765
HumanPheno	Perseverative thought	MLXIPL ARID1B BICRA BCORL1 RFX7 EP300	6.68e-04	377	16	6	HP:0030223
HumanPheno	Thick lower lip vermilion	MLXIPL ARID1B KMT2D SOS1	6.89e-04	136	16	4	HP:0000179
HumanPheno	Abnormal earlobe morphology	MLXIPL KMT2D BICRA EP300	7.09e-04	137	16	4	HP:0000363
HumanPheno	Atrial septal defect	MLXIPL ARID1B KMT2D BICRA KIAA0586 EP300 SOS1	7.11e-04	541	16	7	HP:0001631
HumanPheno	Abnormality of the atrial septum	MLXIPL ARID1B KMT2D BICRA KIAA0586 EP300 SOS1	7.11e-04	541	16	7	HP:0001630
HumanPheno	Abnormal eyelid morphology	MLXIPL TREX1 ARID1B KMT2D BICRA PCLO KIAA0586 BCORL1 RFX7 EP300 SOS1	7.21e-04	1408	16	11	HP:0000492
HumanPheno	Abnormal atrial septum morphology	MLXIPL ARID1B KMT2D BICRA KIAA0586 EP300 SOS1	7.36e-04	544	16	7	HP:0011994
HumanPheno	Frontal bossing	ARID1B KMT2D BICRA KIAA0586 BCORL1 RFX7 EP300 SOS1	8.17e-04	738	16	8	HP:0002007
HumanPheno	Abnormal location of ears	TREX1 ARID1B KMT2D BICRA PCLO KIAA0586 RFX7 EP300 SOS1	8.19e-04	945	16	9	HP:0000357
HumanPheno	Abnormal shape of the frontal region	ARID1B KMT2D BICRA KIAA0586 BCORL1 RFX7 EP300 SOS1	8.40e-04	741	16	8	HP:0011218
HumanPheno	Abnormal stomach morphology	MLXIPL TREX1 ARID1B KMT2D PODXL BICRA KIAA0586 EP300	8.48e-04	742	16	8	HP:0002577
HumanPheno	Abnormal frontal bone morphology	ARID1B KMT2D BICRA KIAA0586 BCORL1 RFX7 EP300 SOS1	8.48e-04	742	16	8	HP:0430000
HumanPheno	Joint hypermobility	MLXIPL ARID1B KMT2D BICRA RFX7 EP300 SOS1	8.50e-04	557	16	7	HP:0001382
HumanPheno	Hypotelorism	MLXIPL ARID1B KMT2D BICRA	9.01e-04	146	16	4	HP:0000601
HumanPheno	Abnormal thought pattern	MLXIPL ARID1B BICRA BCORL1 RFX7 EP300	9.66e-04	404	16	6	HP:5200269
HumanPheno	Hydronephrosis	ARID1B KMT2D RFX7 EP300 SOS1	9.81e-04	264	16	5	HP:0000126
HumanPheno	Low-set ears	TREX1 ARID1B KMT2D BICRA PCLO KIAA0586 EP300 SOS1	1.01e-03	761	16	8	HP:0000369
HumanPheno	Full cheeks	MLXIPL BICRA PCLO EP300	1.02e-03	151	16	4	HP:0000293
HumanPheno	Dental malocclusion	MLXIPL KMT2D EP300 SOS1	1.16e-03	156	16	4	HP:0000689
HumanPheno	Prominent lips	MLXIPL ARID1B KMT2D SOS1	1.16e-03	156	16	4	HP:0000184
HumanPheno	Compulsive behaviors	MLXIPL ARID1B RFX7 EP300	1.21e-03	158	16	4	HP:0000722
HumanPheno	Premature thelarche	KMT2D EP300	1.22e-03	17	16	2	HP:0010314
HumanPheno	Prominent eyelashes	ARID1B KMT2D	1.22e-03	17	16	2	HP:0011231
HumanPheno	Hoarse voice	MLXIPL TREX1 ARID1B DLST	1.24e-03	159	16	4	HP:0001609
HumanPheno	Abnormality of the ulna	MLXIPL BICRA MMP9 SOS1	1.24e-03	159	16	4	HP:0002997
HumanPheno	Abnormal morphology of ulna	MLXIPL BICRA MMP9 SOS1	1.24e-03	159	16	4	HP:0040071
HumanPheno	Hematological neoplasm	TREX1 ARID1B NBEAL2 DLST EP300 SOS1	1.25e-03	424	16	6	HP:0004377
HumanPheno	Feeding difficulties in infancy	MLXIPL TREX1 ARID1B KMT2D KIAA0586 EP300 SOS1	1.26e-03	594	16	7	HP:0008872
HumanPheno	Abnormal cardiac septum morphology	MLXIPL ARID1B KMT2D BICRA KIAA0586 RFX7 EP300 SOS1	1.27e-03	787	16	8	HP:0001671
HumanPheno	Long palpebral fissure	KMT2D PCLO RFX7	1.28e-03	71	16	3	HP:0000637
HumanPheno	Aplasia of the semicircular canal	KMT2D SOS1	1.37e-03	18	16	2	HP:0011381
HumanPheno	Skin appendage neoplasm	KMT2D EP300	1.37e-03	18	16	2	HP:0012842
HumanPheno	Abnormal renal morphology	MLXIPL TREX1 ARID1B KMT2D BICRA KIAA0586 DLST RFX7 EP300 SOS1	1.40e-03	1252	16	10	HP:0012210
HumanPheno	Abnormal calvaria morphology	TREX1 ARID1B KMT2D BICRA PCLO KIAA0586 BCORL1 RFX7 EP300 SOS1	1.42e-03	1254	16	10	HP:0002683
HumanPheno	Abnormal morphology of bones of the upper limbs	MLXIPL BICRA KIAA0586 MMP9 EP300 SOS1	1.45e-03	436	16	6	HP:0040065
HumanPheno	Dilatation of the renal pelvis	ARID1B KMT2D RFX7 EP300 SOS1	1.50e-03	290	16	5	HP:0010946
HumanPheno	Abnormal nasal bridge morphology	MLXIPL ARID1B KMT2D BICRA PCLO KIAA0586 RFX7 EP300 SOS1	1.56e-03	1029	16	9	HP:0000422
HumanPheno	Abnormal cardiac atrium morphology	MLXIPL ARID1B KMT2D BICRA KIAA0586 EP300 SOS1	1.58e-03	617	16	7	HP:0005120
HumanPheno	Abnormality of the hairline	ARID1B KMT2D BICRA EP300 SOS1	1.59e-03	294	16	5	HP:0009553
HumanPheno	Radioulnar synostosis	MLXIPL BICRA SOS1	1.74e-03	79	16	3	HP:0002974
HumanPheno	Abnormal renal pelvis morphology	ARID1B KMT2D RFX7 EP300 SOS1	1.75e-03	300	16	5	HP:0010944
MousePheno	abnormal heart ventricle wall morphology	BICRA MAPK7 MMP9 EP300 CRK SMTN SOS1	1.82e-05	296	40	7	MP:0031532
MousePheno	edema	ARID1B PODXL BICRA KIAA0586 MAPK7 MMP9 EP300 CRK SOS1	3.00e-05	581	40	9	MP:0001785
Domain	Znf_piccolo	PCLO BSN	6.20e-06	2	47	2	IPR008899
Domain	zf-piccolo	PCLO BSN	6.20e-06	2	47	2	PF05715
Domain	PDZ	SHANK2 PCLO SCRIB MAST2	5.59e-04	151	47	4	PS50106
Domain	PDZ	SHANK2 PCLO SCRIB MAST2	5.73e-04	152	47	4	IPR001478
Domain	-	ARID1B ARID3C	6.37e-04	15	47	2	1.10.150.60
Domain	BRIGHT	ARID1B ARID3C	6.37e-04	15	47	2	SM00501
Domain	ARID_dom	ARID1B ARID3C	6.37e-04	15	47	2	IPR001606
Domain	ARID	ARID1B ARID3C	6.37e-04	15	47	2	PS51011
Domain	ARID	ARID1B ARID3C	6.37e-04	15	47	2	PF01388
Domain	Kinase-like_dom	BRSK2 ARHGAP35 MAPK7 BRSK1 MAST2 SOS1	2.27e-03	542	47	6	IPR011009
Domain	MYB_LIKE	EP400 RCOR3	4.11e-03	38	47	2	PS50090
Domain	PDZ	SHANK2 SCRIB MAST2	5.36e-03	141	47	3	PF00595
Domain	Znf_FYVE_PHD	KMT2D PCLO BSN	6.01e-03	147	47	3	IPR011011
Domain	PDZ	SHANK2 SCRIB MAST2	6.13e-03	148	47	3	SM00228
Domain	-	SHANK2 SCRIB MAST2	6.36e-03	150	47	3	2.30.42.10
Domain	SANT	EP400 RCOR3	7.03e-03	50	47	2	SM00717
Domain	SANT/Myb	EP400 RCOR3	7.59e-03	52	47	2	IPR001005
Pathway	REACTOME_SIGNALING_BY_NTRK1_TRKA	IRS2 MAPK7 CRK SOS1	1.92e-05	63	36	4	MM14714
Pathway	WP_ANGIOPOIETINLIKE_PROTEIN_8_REGULATORY_PATHWAY	MLXIPL IRS2 MAPK7 CRK SOS1	1.99e-05	132	36	5	M39338
Pathway	REACTOME_SIGNALING_BY_NTRKS	IRS2 MAPK7 EP300 CRK SOS1	2.14e-05	134	36	5	M3574
Pathway	REACTOME_SIGNALING_BY_NTRKS	IRS2 MAPK7 CRK SOS1	3.83e-05	75	36	4	MM14652
Pathway	PID_IGF1_PATHWAY	IRS2 CRK SOS1	5.34e-05	29	36	3	M125
Pathway	WP_IL3_SIGNALING_PATHWAY	MAPK7 MMP9 CRK SOS1	1.18e-04	100	36	4	MM15879
Pathway	REACTOME_RET_SIGNALING	IRS2 MAPK7 SOS1	1.21e-04	38	36	3	MM15493
Pathway	PID_RET_PATHWAY	IRS2 CRK SOS1	1.31e-04	39	36	3	M82
Pathway	REACTOME_SOS_MEDIATED_SIGNALLING	IRS2 SOS1	1.32e-04	7	36	2	M19489
Pathway	REACTOME_RET_SIGNALING	IRS2 MAPK7 SOS1	1.42e-04	40	36	3	M27746
Pathway	KEGG_PATHWAYS_IN_CANCER	CCDC6 MMP9 EP300 RXRB CRK SOS1	1.56e-04	325	36	6	M12868
Pathway	REACTOME_SIGNALING_BY_PTK6	SFPQ ARHGAP35 CRK	2.44e-04	48	36	3	MM15479
Pathway	REACTOME_SIGNAL_ATTENUATION	IRS2 SOS1	2.82e-04	10	36	2	M14236
Pathway	REACTOME_SIGNAL_ATTENUATION	IRS2 SOS1	2.82e-04	10	36	2	MM15440
Pathway	KEGG_NEUROTROPHIN_SIGNALING_PATHWAY	IRS2 MAPK7 CRK SOS1	2.87e-04	126	36	4	M16763
Pathway	REACTOME_SIGNALING_BY_PTK6	SFPQ ARHGAP35 CRK	3.47e-04	54	36	3	M29742
Pathway	WP_IL4_SIGNALING	IRS2 EP300 SOS1	3.47e-04	54	36	3	M39720
Pathway	WP_KIT_RECEPTOR_SIGNALING	EP300 CRK SOS1	4.51e-04	59	36	3	M39350
Pathway	PID_FAK_PATHWAY	ARHGAP35 CRK SOS1	4.51e-04	59	36	3	M281
Pathway	REACTOME_PTK6_REGULATES_RHO_GTPASES_RAS_GTPASE_AND_MAP_KINASES	ARHGAP35 CRK	4.86e-04	13	36	2	MM15484
Pathway	REACTOME_NR1H2_AND_NR1H3_MEDIATED_SIGNALING	EP300 RXRB	4.86e-04	13	36	2	MM15622
Pathway	REACTOME_NERVOUS_SYSTEM_DEVELOPMENT	IRS2 ARHGAP35 MAPK7 MMP9 SOS1	4.94e-04	261	36	5	MM15676
Pathway	REACTOME_PTK6_REGULATES_RHO_GTPASES_RAS_GTPASE_AND_MAP_KINASES	ARHGAP35 CRK	5.66e-04	14	36	2	M27734
Pathway	REACTOME_ERYTHROPOIETIN_ACTIVATES_RAS	IRS2 SOS1	5.66e-04	14	36	2	M27908
Pathway	REACTOME_SIGNALING_BY_RECEPTOR_TYROSINE_KINASES	IRS2 MAPK7 MMP9 EP300 CRK SOS1	6.00e-04	418	36	6	MM15587
Pathway	WP_INSULIN_SIGNALING	IRS2 MAPK7 CRK SOS1	7.09e-04	160	36	4	M39482
Pathway	REACTOME_GASTRIN_CREB_SIGNALLING_PATHWAY_VIA_PKC_AND_MAPK	MAPK7 SOS1	7.44e-04	16	36	2	MM15477
Pathway	KEGG_RENAL_CELL_CARCINOMA	EP300 CRK SOS1	7.44e-04	70	36	3	M13266
Pathway	WP_KIT_RECEPTOR_SIGNALING_PATHWAY	EP300 CRK SOS1	7.76e-04	71	36	3	MM15947
Pathway	REACTOME_GASTRIN_CREB_SIGNALLING_PATHWAY_VIA_PKC_AND_MAPK	MAPK7 SOS1	9.46e-04	18	36	2	M657
Pathway	WP_FOXA2_PATHWAY	MLXIPL IRS2	1.29e-03	21	36	2	M42579
Pathway	WP_IL2_SIGNALING_PATHWAY	IRS2 CRK SOS1	1.40e-03	87	36	3	MM15915
Pathway	PID_PDGFRA_PATHWAY	CRK SOS1	1.42e-03	22	36	2	M206
Pathway	BIOCARTA_HER2_PATHWAY	EP300 SOS1	1.55e-03	23	36	2	MM1480
Pathway	BIOCARTA_HER2_PATHWAY	EP300 SOS1	1.55e-03	23	36	2	M18719
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	KMT2D SFSWAP EP400 IRS2 SCRIB ARHGAP35 CCDC6 RFX7 PRRC2A SMTN SOS1	1.31e-08	774	51	11	15302935
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	TRNP1 KMT2D SHANK2 EP400 BICRA NBEAL2 PER1 AMBRA1 IRS2 ARHGAP35 MAST2 EP300	5.04e-08	1105	51	12	35748872
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	ARID1B SFSWAP EP400 BICRA PER1 AMBRA1 RCOR3 IRS2 SCRIB MAST2 EP300 SOS1	5.62e-08	1116	51	12	31753913
Pubmed	Interaction network of human early embryonic transcription factors.	ARID1B KMT2D EP400 BICRA BCORL1 RFX7 EP300	7.94e-07	351	51	7	38297188
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	MLXIPL SFPQ SHANK2 PRR36 PCLO BRSK2 DLST SCRIB ARHGAP35 BRSK1 BSN PRRC2A	8.05e-07	1431	51	12	37142655
Pubmed	O-linked N-acetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry.	SHANK2 PCLO BSN	1.07e-06	14	51	3	16452088
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	ARID1B KMT2D EP400 SCRIB ARHGAP35 PRRC2A EP300 CRK	1.28e-06	549	51	8	38280479
Pubmed	PDZ-Containing Proteins Targeted by the ACE2 Receptor.	SHANK2 SCRIB MAST2	1.33e-06	15	51	3	34835087
Pubmed	Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations.	IRS2 MMP9 EP300 RXRB CRK SOS1	1.78e-06	250	51	6	18660489
Pubmed	Identification and functional characterization of transcriptional activators in human cells.	ARID1B KMT2D EP400 BICRA PCLO BCORL1 EP300	1.83e-06	398	51	7	35016035
Pubmed	Bassoon and Piccolo maintain synapse integrity by regulating protein ubiquitination and degradation.	PCLO BSN	2.11e-06	2	51	2	23403927
Pubmed	Role of Bassoon and Piccolo in Assembly and Molecular Organization of the Active Zone.	PCLO BSN	2.11e-06	2	51	2	26793095
Pubmed	An unusual C(2)-domain in the active-zone protein piccolo: implications for Ca(2+) regulation of neurotransmitter release.	PCLO PER1	2.11e-06	2	51	2	11285225
Pubmed	Piccolo and bassoon maintain synaptic vesicle clustering without directly participating in vesicle exocytosis.	PCLO BSN	2.11e-06	2	51	2	20332206
Pubmed	ERK5 regulates invasiveness of osteosarcoma by inducing MMP-9.	MAPK7 MMP9	2.11e-06	2	51	2	22213073
Pubmed	Active zone density is conserved during synaptic growth but impaired in aged mice.	PCLO BSN	2.11e-06	2	51	2	21935939
Pubmed	The IGF-Independent Role of IRS-2 in the Secretion of MMP-9 Enhances the Growth of Prostate Carcinoma Cell Line PC3.	IRS2 MMP9	2.11e-06	2	51	2	37894751
Pubmed	SAD: a presynaptic kinase associated with synaptic vesicles and the active zone cytomatrix that regulates neurotransmitter release.	BRSK2 BRSK1	2.11e-06	2	51	2	16630837
Pubmed	Role of electrostatic interactions in binding of peptides and intrinsically disordered proteins to their folded targets. 1. NMR and MD characterization of the complex between the c-Crk N-SH3 domain and the peptide Sos.	CRK SOS1	2.11e-06	2	51	2	25207671
Pubmed	Dual-color STED microscopy reveals a sandwich structure of Bassoon and Piccolo in active zones of adult and aged mice.	PCLO BSN	2.11e-06	2	51	2	27321892
Pubmed	No symphony without bassoon and piccolo: changes in synaptic active zone proteins in Huntington's disease.	PCLO BSN	2.11e-06	2	51	2	32493491
Pubmed	Investigating the regulation of brain-specific kinases 1 and 2 by phosphorylation.	BRSK2 BRSK1	2.11e-06	2	51	2	18339622
Pubmed	Synaptic activity controls localization and function of CtBP1 via binding to Bassoon and Piccolo.	PCLO BSN	2.11e-06	2	51	2	25652077
Pubmed	Isozyme-Specific Role of SAD-A in Neuronal Migration During Development of Cerebral Cortex.	BRSK2 BRSK1	2.11e-06	2	51	2	30307479
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	ARID1B KMT2D BCORL1 RCOR3 DLST IRS2 BSN EP300	3.90e-06	638	51	8	31182584
Pubmed	Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells.	IRS2 SOS1	6.32e-06	3	51	2	9651378
Pubmed	The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS. Modulation by insulin growth factor-I (IGF) and enhanced IGF-I signaling.	IRS2 CRK	6.32e-06	3	51	2	8621590
Pubmed	Synapses of amphids defective (SAD-A) kinase promotes glucose-stimulated insulin secretion through activation of p21-activated kinase (PAK1) in pancreatic β-Cells.	BRSK2 BRSK1	6.32e-06	3	51	2	22669945
Pubmed	The KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression.	KMT2D EP300	6.32e-06	3	51	2	37410700
Pubmed	Persistence of the cell-cycle checkpoint kinase Wee1 in SadA- and SadB-deficient neurons disrupts neuronal polarity.	BRSK2 BRSK1	6.32e-06	3	51	2	20026642
Pubmed	Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300.	EP400 EP300	6.32e-06	3	51	2	9590171
Pubmed	Microtubule stabilization specifies initial neuronal polarization.	BRSK2 BRSK1	6.32e-06	3	51	2	18268107
Pubmed	ERK5 silencing inhibits invasion of human osteosarcoma cell via modulating the Slug/MMP-9 pathway.	MAPK7 MMP9	6.32e-06	3	51	2	25317798
Pubmed	A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription.	KMT2D EP300	6.32e-06	3	51	2	28732206
Pubmed	Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.	ARID1B KMT2D EP400 EP300	6.92e-06	83	51	4	28794006
Pubmed	An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency.	ARID1B SFPQ BICRA	1.06e-05	29	51	3	19279220
Pubmed	Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations.	SHANK2 PCLO BRSK2 BSN PRRC2A SOS1	1.17e-05	347	51	6	17114649
Pubmed	Targeting the p300/NONO axis sensitizes melanoma cells to BRAF inhibitors.	SFPQ AMBRA1 EP300	1.17e-05	30	51	3	34017080
Pubmed	MLL3/MLL4 are required for CBP/p300 binding on enhancers and super-enhancer formation in brown adipogenesis.	KMT2D EP300	1.26e-05	4	51	2	28398509
Pubmed	Tuberous sclerosis complex proteins control axon formation.	BRSK2 BRSK1	1.26e-05	4	51	2	18794346
Pubmed	Insulin stimulates the tyrosine dephosphorylation of docking protein p130cas (Crk-associated substrate), promoting the switch of the adaptor protein crk from p130cas to newly phosphorylated insulin receptor substrate-1.	IRS2 CRK	1.26e-05	4	51	2	9729467
Pubmed	Binding and modulation of p53 by p300/CBP coactivators.	EP400 EP300	1.26e-05	4	51	2	9194565
Pubmed	H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids.	MLXIPL TREX1 SFPQ KMT2D SFSWAP EP400 BCORL1 RCOR3 RFX7 EP300	1.56e-05	1294	51	10	30804502
Pubmed	Human SAD1 kinase is involved in UV-induced DNA damage checkpoint function.	BRSK2 BRSK1	2.10e-05	5	51	2	15150265
Pubmed	C-terminal phosphorylation of LKB1 is not required for regulation of AMP-activated protein kinase, BRSK1, BRSK2, or cell cycle arrest.	BRSK2 BRSK1	2.10e-05	5	51	2	18854318
Pubmed	RhoA/ROCK activation by growth hormone abrogates p300/histone deacetylase 6 repression of Stat5-mediated transcription.	ARHGAP35 EP300	2.10e-05	5	51	2	15102857
Pubmed	Platelet Extracellular Regulated Protein Kinase 5 Is a Redox Switch and Triggers Maladaptive Platelet Responses and Myocardial Infarct Expansion.	MAPK7 MMP9	2.10e-05	5	51	2	25934838
Pubmed	Cited2 modulates TGF-beta-mediated upregulation of MMP9.	MMP9 EP300	2.10e-05	5	51	2	16619037
Pubmed	Structural basis for the transforming activity of human cancer-related signaling adaptor protein CRK.	CRK SOS1	2.10e-05	5	51	2	17515907
Pubmed	Distinct roles of DBHS family members in the circadian transcriptional feedback loop.	SFPQ PER1	2.10e-05	5	51	2	22966205
Pubmed	Comprehensive identification of phosphorylation sites in postsynaptic density preparations.	SHANK2 PCLO ARHGAP35 BSN PRRC2A	2.27e-05	231	51	5	16452087
Pubmed	Spatiotemporal-resolved protein networks profiling with photoactivation dependent proximity labeling.	SFPQ SFSWAP BICRA EIF5 SCRIB PRRC2A	2.56e-05	399	51	6	35987950
Pubmed	Roles of tau protein in health and disease.	BRSK2 BRSK1 EP300	2.82e-05	40	51	3	28386764
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	ARID1B SFPQ KMT2D EP400 BICRA BCORL1 EIF5 PRRC2A EP300	2.88e-05	1103	51	9	34189442
Pubmed	Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice.	MLXIPL EP300	3.15e-05	6	51	2	21084751
Pubmed	A protein interaction node at the neurotransmitter release site: domains of Aczonin/Piccolo, Bassoon, CAST, and rim converge on the N-terminal domain of Munc13-1.	PCLO BSN	3.15e-05	6	51	2	19812333
Pubmed	SAD kinases control the maturation of nerve terminals in the mammalian peripheral and central nervous systems.	BRSK2 BRSK1	3.15e-05	6	51	2	24395778
Pubmed	LKB1 and AMPK regulate synaptic remodeling in old age.	BRSK2 BRSK1	3.15e-05	6	51	2	25086610
Pubmed	Mammalian SAD kinases are required for neuronal polarization.	BRSK2 BRSK1	3.15e-05	6	51	2	15705853
Pubmed	Physical and functional interaction of the active zone proteins, CAST, RIM1, and Bassoon, in neurotransmitter release.	PCLO BSN	3.15e-05	6	51	2	14734538
Pubmed	Coactivation of the CLOCK-BMAL1 complex by CBP mediates resetting of the circadian clock.	PER1 EP300	3.15e-05	6	51	2	20930143
Pubmed	Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats.	ARID1B KMT2D	3.15e-05	6	51	2	8896557
Pubmed	Matrix metalloproteinase 2 and 9 dysfunction underlie vascular stiffness in circadian clock mutant mice.	PER1 MMP9	3.15e-05	6	51	2	20829506
Pubmed	Phosphorylation of microtubule-associated protein tau by AMPK-related kinases.	BRSK2 BRSK1	3.15e-05	6	51	2	21985311
Pubmed	Insulin substrates 1 and 2 are corequired for activation of atypical protein kinase C and Cbl-dependent phosphatidylinositol 3-kinase during insulin action in immortalized brown adipocytes.	IRS2 CRK	3.15e-05	6	51	2	15581362
Pubmed	Degradation, Promoter Recruitment and Transactivation Mediated by the Extreme N-Terminus of MHC Class II Transactivator CIITA Isoform III.	EP400 EP300	3.15e-05	6	51	2	26871568
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	MLXIPL EIF5 BRSK2 IRS2 SCRIB CCDC6 RFX7 MAST2	3.39e-05	861	51	8	36931259
Pubmed	Proteomic Analysis of the EWS-Fli-1 Interactome Reveals the Role of the Lysosome in EWS-Fli-1 Turnover.	SFSWAP BICRA PCLO BCORL1 EP300 SMTN	3.64e-05	425	51	6	24999758
Pubmed	Human transcription factor protein interaction networks.	ARID1B KMT2D MIDN EP400 BICRA BCORL1 RCOR3 RFX7 PRRC2A EP300	3.64e-05	1429	51	10	35140242
Pubmed	Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes.	KMT2D MMP9	4.41e-05	7	51	2	19219072
Pubmed	LPCAT3 Is Transcriptionally Regulated by YAP/ZEB/EP300 and Collaborates with ACSL4 and YAP to Determine Ferroptosis Sensitivity.	KMT2D EP300	4.41e-05	7	51	2	37166352
Pubmed	Interactions between Src homology (SH) 2/SH3 adapter proteins and the guanylnucleotide exchange factor SOS are differentially regulated by insulin and epidermal growth factor.	CRK SOS1	4.41e-05	7	51	2	8810325
Pubmed	Characterization of the CIN85 adaptor protein and identification of components involved in CIN85 complexes.	CRK SOS1	5.87e-05	8	51	2	11071869
Pubmed	The GTPase dynamin binds to and is activated by a subset of SH3 domains.	CRK SOS1	5.87e-05	8	51	2	8402898
Pubmed	Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis.	PODXL BCORL1 EIF5 RCOR3 DLST ARHGAP35 MAST2	6.31e-05	689	51	7	36543142
Pubmed	The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers.	ARID1B SFPQ SFSWAP EP400 BICRA BCORL1 EIF5 PRRC2A	6.97e-05	954	51	8	36373674
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	SFPQ SHANK2 PRR36 SCRIB CCDC6 BRSK1 BSN PRRC2A	7.44e-05	963	51	8	28671696
Pubmed	The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation.	SFPQ BICRA RFX7 EP300	7.47e-05	152	51	4	38360978
Pubmed	B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK.	PPP2R5B MAPK7	7.54e-05	9	51	2	16456541
Pubmed	TNF-alpha induces matrix metalloproteinase-9 expression in A549 cells: role of TNFR1/TRAF2/PKCalpha-dependent signaling pathways.	MMP9 EP300	7.54e-05	9	51	2	20333651
Pubmed	Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.	CRK SOS1	7.54e-05	9	51	2	8978305
Pubmed	Polarity inversion reorganizes the stem cell compartment of the trophoblast lineage.	PODXL SCRIB	7.54e-05	9	51	2	36989113
Pubmed	B cell antigen receptor signaling induces the formation of complexes containing the Crk adapter proteins.	CRK SOS1	7.54e-05	9	51	2	8943292
Pubmed	Superresolution imaging of chemical synapses in the brain.	PCLO BSN	7.54e-05	9	51	2	21144999
Pubmed	The Epigenetic Factor Landscape of Developing Neocortex Is Regulated by Transcription Factors Pax6→ Tbr2→ Tbr1.	ARID1B KMT2D EP400 EP300	8.47e-05	157	51	4	30186101
Pubmed	Nomenclature of the ARID family of DNA-binding proteins.	ARID1B ARID3C	9.42e-05	10	51	2	15922553
Pubmed	Purification and identification of protein-tyrosine kinase-binding proteins using synthetic phosphopeptides as affinity reagents.	SFPQ SOS1	1.15e-04	11	51	2	15215307
Pubmed	Deciphering epiblast lumenogenesis reveals proamniotic cavity control of embryo growth and patterning.	PODXL SCRIB	1.15e-04	11	51	2	33692105
Pubmed	A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning.	MLXIPL TEPSIN SHANK2 EIF5 PER1 IRS2 MAPK7 CCDC6	1.25e-04	1038	51	8	26673895
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	ARID1B KMT2D PPP2R5B PPP1R11 RELL1 SCRIB CCDC6 PRRC2A	1.34e-04	1049	51	8	27880917
Pubmed	Interaction of PDK1 with phosphoinositides is essential for neuronal differentiation but dispensable for neuronal survival.	BRSK2 BRSK1	1.38e-04	12	51	2	23275438
Pubmed	Multiple roles of integrin-α3 at the neuromuscular junction.	PCLO BSN	1.38e-04	12	51	2	28386022
Pubmed	Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy.	MLXIPL PODXL	1.38e-04	12	51	2	24717294
Pubmed	Histone acetyltransferase-dependent chromatin remodeling and the vascular clock.	PER1 EP300	1.38e-04	12	51	2	14645221
Pubmed	Multifaceted Regulation of Akt by Diverse C-Terminal Post-translational Modifications.	SHANK2 AMBRA1 PPP1R11	1.45e-04	69	51	3	34941261
Pubmed	The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes.	KMT2D EP400	1.63e-04	13	51	2	16510874
Pubmed	A Point Mutation in p190A RhoGAP Affects Ciliogenesis and Leads to Glomerulocystic Kidney Defects.	PODXL ARHGAP35	1.63e-04	13	51	2	26859289
Pubmed	The SCF-FBXW7 E3 ubiquitin ligase triggers degradation of histone 3 lysine 4 methyltransferase complex component WDR5 to prevent mitotic slippage.	KMT2D PRR36	1.63e-04	13	51	2	36395886
Pubmed	The loss of the kinases SadA and SadB results in early neuronal apoptosis and a reduced number of progenitors.	BRSK2 BRSK1	1.63e-04	13	51	2	29698519
Pubmed	A molecular mechanism for circadian clock negative feedback.	SFPQ PER1	1.63e-04	13	51	2	21680841
Interaction	KLF3 interactions	ARID1B KMT2D EP400 BCORL1 RCOR3 RFX7 EP300	1.64e-06	228	51	7	int:KLF3
Interaction	EGR2 interactions	ARID1B KMT2D EP400 BICRA BCORL1 EP300	4.49e-06	171	51	6	int:EGR2
Interaction	KLF15 interactions	KMT2D EP400 IGHA1 BCORL1 PRRC2A EP300 CRK	8.00e-06	290	51	7	int:KLF15
Interaction	TOP3B interactions	TRNP1 KMT2D SHANK2 EP400 BICRA NBEAL2 PER1 AMBRA1 DLST IRS2 ARHGAP35 MAST2 PRRC2A EP300	1.13e-05	1470	51	14	int:TOP3B
Interaction	ETS1 interactions	ARID1B KMT2D EP400 MAPK7 EP300	1.35e-05	121	51	5	int:ETS1
Interaction	YWHAZ interactions	MLXIPL SFPQ NBEAL2 EIF5 DLST IRS2 SCRIB MAPK7 CCDC6 MAST2 PRRC2A EP300 CRK	1.74e-05	1319	51	13	int:YWHAZ
Interaction	NR3C1 interactions	ARID1B SFPQ KMT2D BCORL1 RCOR3 DLST IRS2 CCDC6 BSN EP300 RXRB	2.55e-05	974	51	11	int:NR3C1
Interaction	GCM1 interactions	ARID1B KMT2D RCOR3 EP300	2.63e-05	68	51	4	int:GCM1
Interaction	KCTD13 interactions	MLXIPL SFPQ SHANK2 PRR36 PCLO BRSK2 DLST SCRIB ARHGAP35 BRSK1 BSN PRRC2A CRK	3.13e-05	1394	51	13	int:KCTD13
Interaction	PAX6 interactions	ARID1B KMT2D EP400 BICRA RCOR3 CCDC6 EP300	3.58e-05	366	51	7	int:PAX6
Interaction	ASF1A interactions	ARID1B KMT2D EP400 BICRA BCORL1 EP300	3.79e-05	249	51	6	int:ASF1A
Interaction	CRX interactions	ARID1B KMT2D EP400 BICRA BCORL1 EP300	4.23e-05	254	51	6	int:CRX
Interaction	YWHAE interactions	SFPQ MIDN EIF5 BRSK2 DLST IRS2 MAPK7 CCDC6 BRSK1 MAST2 PRRC2A CRK	5.34e-05	1256	51	12	int:YWHAE
Interaction	SOX7 interactions	ARID1B KMT2D BCORL1 EP300	5.50e-05	82	51	4	int:SOX7
Interaction	HNF4A interactions	ARID1B KMT2D EP400 BICRA RCOR3 EP300	6.58e-05	275	51	6	int:HNF4A
Interaction	GSC interactions	ARID1B KMT2D BCORL1 EP300	6.93e-05	87	51	4	int:GSC
Interaction	KNDC1 interactions	TEPSIN PPP2R5B BRSK2	7.19e-05	32	51	3	int:KNDC1
Interaction	NR1H4 interactions	MLXIPL EP300 RXRB	7.19e-05	32	51	3	int:NR1H4
Interaction	FOXI1 interactions	ARID1B KMT2D RCOR3 EP300	8.62e-05	92	51	4	int:FOXI1
Interaction	ALG13 interactions	ARID1B KMT2D RCOR3 PRRC2A EP300	9.79e-05	183	51	5	int:ALG13
Interaction	E2F5 interactions	ARID1B KMT2D EP300	1.03e-04	36	51	3	int:E2F5
Interaction	HOXB2 interactions	ARID1B KMT2D EP300	1.03e-04	36	51	3	int:HOXB2
Interaction	SOX9 interactions	ARID1B KMT2D EP400 EP300	1.06e-04	97	51	4	int:SOX9
Interaction	SP7 interactions	ARID1B KMT2D EP400 BICRA RCOR3 EP300	1.14e-04	304	51	6	int:SP7
Interaction	HNF1B interactions	ARID1B KMT2D EP400 BICRA EP300	1.17e-04	190	51	5	int:HNF1B
Interaction	PPARG interactions	ARID1B SFPQ KMT2D BICRA EP300 RXRB	1.20e-04	307	51	6	int:PPARG
Interaction	MYOD1 interactions	MLXIPL ARID1B KMT2D EP400 EP300	1.29e-04	194	51	5	int:MYOD1
Interaction	FOS interactions	ARID1B KMT2D MIDN EP400 MAPK7 EP300	1.32e-04	312	51	6	int:FOS
Interaction	KLF5 interactions	ARID1B KMT2D EP400 PRRC2A EP300	1.32e-04	195	51	5	int:KLF5
Interaction	FEV interactions	ARID1B KMT2D EP400 BICRA EP300	1.59e-04	203	51	5	int:FEV
Interaction	ERC2 interactions	PCLO CCDC6 BSN	1.63e-04	42	51	3	int:ERC2
Interaction	EN1 interactions	KMT2D EP400 SCRIB EP300	1.72e-04	110	51	4	int:EN1
Interaction	KLF8 interactions	KMT2D EP400 BICRA BCORL1 PRRC2A EP300	1.75e-04	329	51	6	int:KLF8
Interaction	PPP2CA interactions	PPP2R5B EP400 PER1 AMBRA1 CCDC6 C3orf36 EP300	2.05e-04	484	51	7	int:PPP2CA
Interaction	TBXT interactions	ARID1B KMT2D RCOR3 EP300	2.11e-04	116	51	4	int:TBXT
Interaction	RFPL4B interactions	PER1 AMBRA1 ZNF446	2.44e-04	48	51	3	int:RFPL4B
Interaction	NR1I2 interactions	MAPK7 EP300 RXRB	2.44e-04	48	51	3	int:NR1I2
Interaction	ERG interactions	ARID1B SFPQ KMT2D BICRA EP300	2.46e-04	223	51	5	int:ERG
Interaction	PAX7 interactions	ARID1B KMT2D RCOR3 EP300	2.73e-04	124	51	4	int:PAX7
Interaction	PAX9 interactions	TEPSIN ARID1B KMT2D EP300	3.27e-04	130	51	4	int:PAX9
Interaction	SOCS6 interactions	AMBRA1 RCOR3 IRS2 CRK	3.27e-04	130	51	4	int:SOCS6
Interaction	WEE1 interactions	BRSK2 BRSK1 EP300 CRK	3.56e-04	133	51	4	int:WEE1
Interaction	YWHAH interactions	MLXIPL SFSWAP EIF5 IRS2 SCRIB MAPK7 CCDC6 RFX7 MAST2 CRK	3.77e-04	1102	51	10	int:YWHAH
Interaction	EWSR1 interactions	SFPQ SFSWAP BICRA PCLO BCORL1 PER1 PRRC2A EP300 SMTN	4.00e-04	906	51	9	int:EWSR1
Interaction	SELENOP interactions	EP400 EP300	4.08e-04	12	51	2	int:SELENOP
Interaction	CCDC148 interactions	IGHA1 TEX9	4.08e-04	12	51	2	int:CCDC148
Interaction	YWHAQ interactions	MLXIPL EIF5 RCOR3 DLST IRS2 SCRIB CCDC6 RFX7 MAST2 CRK	4.22e-04	1118	51	10	int:YWHAQ
Interaction	GOLGA2 interactions	TEPSIN KMT2D BICRA RCOR3 CCDC6 TEX9 EP300 RXRB	4.70e-04	733	51	8	int:GOLGA2
Interaction	ARHGAP42 interactions	ARHGAP35 CRK SOS1	4.72e-04	60	51	3	int:ARHGAP42
Interaction	CTBP1 interactions	SFPQ EP400 PCLO BCORL1 RCOR3 EP300	5.39e-04	406	51	6	int:CTBP1
Interaction	SUPT5H interactions	ARID1B KMT2D EP400 BICRA RCOR3 EP300	5.53e-04	408	51	6	int:SUPT5H
Cytoband	3p21.31	TREX1 NBEAL2 BSN	1.94e-04	100	51	3	3p21.31
Cytoband	15q21.3	TEX9 RFX7	7.03e-04	35	51	2	15q21.3
Cytoband	12q24.33	SFSWAP EP400	1.32e-03	48	51	2	12q24.33
Cytoband	6p21.3	PPP1R11 PRRC2A RXRB	2.74e-03	250	51	3	6p21.3
Cytoband	19q13.3	BICRA ARHGAP35	3.80e-03	82	51	2	19q13.3
Cytoband	Ensembl 112 genes in cytogenetic band chr3p21	TREX1 NBEAL2 BSN	5.27e-03	316	51	3	chr3p21
GeneFamily	PDZ domain containing	SHANK2 PCLO SCRIB MAST2	1.11e-04	152	30	4	1220
GeneFamily	AT-rich interaction domain containing	ARID1B ARID3C	2.76e-04	15	30	2	418
GeneFamily	Zinc fingers\|Zinc fingers PARP-type\|Poly(ADP-ribose) polymerases	PCLO BSN	2.76e-04	15	30	2	26
GeneFamily	Ataxins\|Trinucleotide repeat containing	KMT2D EP400	7.80e-04	25	30	2	775
GeneFamily	GATA zinc finger domain containing\|Myb/SANT domain containing	EP400 RCOR3	3.48e-03	53	30	2	532
Coexpression	BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP	SFPQ PPP2R5B SFSWAP EIF5 PER1 IRS2 MAPK7 EP300 SOS1	2.62e-05	822	51	9	M6782
Coexpression	GSE21063_CTRL_VS_ANTI_IGM_STIM_BCELL_NFATC1_KO_8H_UP	KMT2D MIDN NBEAL2 PER1 MMP9	3.58e-05	192	51	5	M8272
Coexpression	GSE23505_UNTREATED_VS_4DAY_IL6_IL1_IL23_TREATED_CD4_TCELL_UP	SFSWAP EIF5 IRS2 RELL1 MAPK7	4.35e-05	200	51	5	M7856
Coexpression	GSE1432_6H_VS_24H_IFNG_MICROGLIA_UP	SFPQ PPP2R5B PODXL MAST2 EP300	4.35e-05	200	51	5	M3415
ToppCell	390C-Lymphocytic-CD4_T-cell-CD4+_Effector_T_cell-2\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	MMP9 MAST2 EP300 B3GNT8 SOS1	1.61e-06	173	51	5	b9dee61973559e8c2fef3f2dafd43475b386befb
ToppCell	facs-Mammary_Gland-Mammary_Gland-21m\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SFPQ MIDN PER1 IRS2 PRRC2A	2.30e-06	186	51	5	bd1185592aedebccd1007dbf2dd2f549fcdf9f42
ToppCell	facs-Mammary_Gland-Mammary_Gland-21m-Epithelial\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SFPQ MIDN PER1 IRS2 PRRC2A	2.49e-06	189	51	5	965e0e388251e7318f8b463816dc96ccb4658677
ToppCell	wk_08-11-Epithelial-Proximal_epithelial-intermediate_neuroendocrine\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	TRNP1 MLXIPL PCLO BRSK2 BSN	2.56e-06	190	51	5	5f1863bce9400b7c932f0e4d0e012ec4e8d7e555
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	ARID1B SHANK2 AMBRA1 RFX7 SOS1	2.98e-06	196	51	5	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	ARID1B SHANK2 AMBRA1 RFX7 SOS1	3.21e-06	199	51	5	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	5'-Adult-Distal_Rectal-Epithelial-goblet-BEST2+_Goblet_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PRR36 IRS2 SCRIB SMTN	4.79e-05	175	51	4	019ea30ac55748463d7917abf3d3f0e804189bfd
ToppCell	5'-Adult-Distal_Rectal-Epithelial-goblet\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PRR36 IRS2 SCRIB SMTN	5.12e-05	178	51	4	9099b47e0756d6a1b7ba1c6aa7b47c5425f649e0
ToppCell	(1)_B_cells-(1)_B_CD27pos\|(1)_B_cells / Oesophagus cell shreds on cell class (v1) and cell subclass (v1)	MIDN IGHA1 EIF5 TEX9	5.46e-05	181	51	4	d2476956ca13f9234d7e77c3ee432dd54eebeac4
ToppCell	B_cells-Naive_B_cells_\|B_cells / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	SFPQ MIDN PER1 IRS2	7.58e-05	197	51	4	fd5fdc5289d681d59ff22d72e4de6e74c6c7aac6
ToppCell	Sepsis-URO\|Sepsis / Disease, condition lineage and cell class	NBEAL2 PER1 IRS2 BRSK1	7.89e-05	199	51	4	8e6dac82d1d0e759cd567f9c95b70cb4801d7caf
ToppCell	Parenchymal-10x3prime_v2-Stromal-Myofibroblastic-Muscle_smooth_pulmonary\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	TRNP1 VASN BRSK2 SMTN	7.89e-05	199	51	4	2ed10c5e15c9d5ed0a8bea580842348d5698a07b
ToppCell	COVID-19\|World / Disease, condition lineage and cell class	ARID1B SFPQ IGHA1 EIF5	8.04e-05	200	51	4	7dec470c379cd89f05a0f37c8628b21f136e52f0
ToppCell	mLN-Dendritic_cell-cDC2\|Dendritic_cell / Region, Cell class and subclass	MIDN MMP9 RFX7 CRK	8.04e-05	200	51	4	e3f7852aaa26a9b3e626d85e40afde799e873045
ToppCell	COVID-19-COVID-19_Mild\|COVID-19 / Disease, condition lineage and cell class	ARID1B SFPQ MIDN PER1	8.04e-05	200	51	4	62c25042086f1afd1102e0720e933c2e476468fd
ToppCell	Influenza\|World / Disease, condition lineage and cell class	MIDN NBEAL2 PER1 IRS2	8.04e-05	200	51	4	df996c35907a1c9194b9e2ca30e81f520ca067f0
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW13-Mesenchymal-Mesoderm\|GW13 / Sample Type, Dataset, Time_group, and Cell type.	TREX1 PER1 RFX7 ZNF446	8.04e-05	200	51	4	0f4b8b0868bda406fe6bf01d1b722510fdfd0168
Drug	Isoniazid [54-85-3]; Down 200; 29.2uM; PC3; HT_HG-U133A	PPP2R5B BCORL1 AMBRA1 MAPK7 MMP9 SMTN	4.78e-06	195	51	6	5840_DN
Drug	Cyclopenthiazide [742-20-1]; Up 200; 10.6uM; MCF7; HT_HG-U133A	PPP2R5B PRR36 NBEAL2 PER1 MAPK7 SMTN	4.78e-06	195	51	6	4813_UP
Drug	Monensin sodium salt [22373-78-0]; Down 200; 5.8uM; MCF7; HT_HG-U133A	PPP2R5B SFSWAP PRR36 KIAA0586 MAPK7 ZNF446	5.06e-06	197	51	6	4726_DN
Drug	Methapyrilene hydrochloride [135-23-9]; Up 200; 13.4uM; MCF7; HT_HG-U133A	PPP2R5B PRR36 PCLO IRS2 MAPK7 ZNF446	5.37e-06	199	51	6	4990_UP
Drug	Xylometazoline hydrochloride [1218-35-5]; Down 200; 14.2uM; MCF7; HT_HG-U133A	EP400 NBEAL2 KIAA0586 AMBRA1 MMP9 MAST2	5.37e-06	199	51	6	7020_DN
Drug	(R)-(+)-Atenolol [56715-13-0]; Down 200; 15uM; MCF7; HT_HG-U133A	PRR36 BCORL1 AMBRA1 IRS2 ARHGAP35 SOS1	5.52e-06	200	51	6	4841_DN
Drug	Glutethimide, para-amino [125-84-8]; Up 200; 17.2uM; MCF7; HT_HG-U133A	PPP2R5B PRR36 EIF5 PER1 IRS2 ZNF446	5.52e-06	200	51	6	7463_UP
Drug	casticin	EIF5 RCOR3 PPP1R11 MMP9 EP300 SOS1	2.06e-05	252	51	6	ctd:C054133
Drug	LYR 71	MMP9 EP300	2.94e-05	4	51	2	ctd:C530478
Drug	MS-275; Down 200; 10uM; PC3; HT_HG-U133A	SFSWAP MAPK7 CCDC6 CRK SOS1	6.44e-05	189	51	5	7074_DN
Drug	ICI 182,780; Up 200; 0.01uM; MCF7; HT_HG-U133A_EA	BCORL1 AMBRA1 RCOR3 ARHGAP35 RFX7	6.94e-05	192	51	5	1076_UP
Drug	GSK-3beta Inhibitor VIII; Down 200; 10uM; MCF7; HT_HG-U133A	SFPQ EIF5 PER1 IRS2 SOS1	6.94e-05	192	51	5	7092_DN
Drug	Muramic acid, N-acetyl [10597-89-4]; Up 200; 13.6uM; MCF7; HT_HG-U133A	BCORL1 PER1 AMBRA1 MAPK7 PRRC2A	7.11e-05	193	51	5	3262_UP
Drug	lomustine; Down 200; 100uM; MCF7; HT_HG-U133A	BCORL1 EIF5 PER1 AMBRA1 SMTN	7.29e-05	194	51	5	7089_DN
Drug	Sulfaquinoxaline sodium salt [967-80-6]; Down 200; 12.4uM; MCF7; HT_HG-U133A	PPP2R5B BCORL1 PER1 IRS2 SMTN	7.29e-05	194	51	5	6090_DN
Drug	H-89, Dihydrochloride; Up 200; 0.5uM; PC3; HT_HG-U133A	PCLO PER1 CCDC6 MMP9 PRRC2A	7.29e-05	194	51	5	6921_UP
Drug	Tridihexethyl chloride; Up 200; 11.4uM; MCF7; HT_HG-U133A	PRR36 BICRA ARHGAP35 MAST2 PRRC2A	7.29e-05	194	51	5	3526_UP
Drug	Urapidil hydrochloride [64887-14-5]; Up 200; 9.4uM; HL60; HT_HG-U133A	MLXIPL PCLO ARHGAP35 MAPK7 MAST2	7.47e-05	195	51	5	3078_UP
Drug	Isoetharine mesylate salt [7279-75-6]; Down 200; 12uM; MCF7; HT_HG-U133A	SFPQ PODXL NBEAL2 AMBRA1 MAST2	7.47e-05	195	51	5	3451_DN
Drug	Acacetin [480-44-4]; Down 200; 14uM; PC3; HT_HG-U133A	PPP2R5B ARHGAP35 MMP9 PRRC2A ZNF446	7.47e-05	195	51	5	4324_DN
Drug	Aconitine [302-27-2]; Down 200; 6.2uM; MCF7; HT_HG-U133A	PPP2R5B SHANK2 IRS2 ARHGAP35 MAST2	7.47e-05	195	51	5	2776_DN
Drug	haloperidol; Up 200; 10uM; MCF7; HT_HG-U133A_EA	EP400 PER1 AMBRA1 IRS2 EP300	7.65e-05	196	51	5	1041_UP
Drug	Ronidazole [7681-76-7]; Up 200; 20uM; PC3; HT_HG-U133A	PPP2R5B BCORL1 PER1 IRS2 MAPK7	7.65e-05	196	51	5	7131_UP
Drug	Rolitetracycline [751-97-3]; Down 200; 7.6uM; MCF7; HT_HG-U133A	SHANK2 SFSWAP PODXL AMBRA1 SMTN	7.65e-05	196	51	5	5331_DN
Drug	Fluorometholone [426-13-1]; Down 200; 10.6uM; MCF7; HT_HG-U133A	SFPQ NBEAL2 AMBRA1 MAST2 SMTN	7.65e-05	196	51	5	6247_DN
Drug	Doxazosin mesylate [77883-43-3]; Down 200; 7.4uM; MCF7; HT_HG-U133A	SHANK2 BICRA NBEAL2 ARHGAP35 MAST2	7.84e-05	197	51	5	4988_DN
Drug	Mephenytoin [50-12-4]; Down 200; 18.4uM; MCF7; HT_HG-U133A	EP400 BICRA EIF5 ARHGAP35 MAST2	7.84e-05	197	51	5	6275_DN
Drug	Picrotoxinin [17617-45-7]; Up 200; 13.6uM; HL60; HT_HG-U133A	PCLO ARHGAP35 MAPK7 MMP9 SMTN	7.84e-05	197	51	5	2161_UP
Drug	Metyrapone [54-36-4]; Down 200; 17.6uM; PC3; HT_HG-U133A	BCORL1 EIF5 AMBRA1 MAST2 SOS1	7.84e-05	197	51	5	4606_DN
Drug	Canrenoic acid potassium salt [2181-04-6]; Up 200; 10uM; PC3; HT_HG-U133A	SHANK2 PRR36 BCORL1 PER1 AMBRA1	8.03e-05	198	51	5	2065_UP
Drug	Ticarcillin sodium [4697-14-7]; Up 200; 9.4uM; PC3; HT_HG-U133A	NBEAL2 AMBRA1 ARHGAP35 MAST2 SOS1	8.03e-05	198	51	5	5829_UP
Drug	(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Down 200; 11.8uM; PC3; HT_HG-U133A	SHANK2 EIF5 ARHGAP35 MAPK7 SOS1	8.03e-05	198	51	5	4546_DN
Drug	Procaine hydrochloride [51-05-8]; Down 200; 14.6uM; HL60; HT_HG-U133A	SFSWAP EP400 NBEAL2 CCDC6 CRK	8.03e-05	198	51	5	1838_DN
Drug	Quinidine hydrochloride monohydrate [6151-40-2]; Up 200; 10.6uM; MCF7; HT_HG-U133A	PRR36 PODXL IRS2 MMP9 SMTN	8.03e-05	198	51	5	6267_UP
Drug	Pyrantel tartrate [33401-94-4]; Down 200; 11.2uM; MCF7; HT_HG-U133A	PCLO RCOR3 ARHGAP35 MAST2 SOS1	8.22e-05	199	51	5	5513_DN
Drug	Ribavirin [36791-04-5]; Down 200; 16.4uM; PC3; HT_HG-U133A	SHANK2 EIF5 AMBRA1 MMP9 SMTN	8.22e-05	199	51	5	7316_DN
Drug	Cyproheptadine hydrochloride [969-33-5]; Up 200; 12.4uM; MCF7; HT_HG-U133A	PPP2R5B IRS2 MAPK7 MAST2 SMTN	8.22e-05	199	51	5	1521_UP
Drug	Trolox [53188-07-1]; Up 200; 16uM; MCF7; HT_HG-U133A	SHANK2 PER1 IRS2 MAPK7 ZNF446	8.22e-05	199	51	5	2883_UP
Drug	Dacarbazine [4342-03-4]; Down 200; 22uM; MCF7; HT_HG-U133A	PODXL BICRA BCORL1 MMP9 SMTN	8.22e-05	199	51	5	2754_DN
Drug	Chlorambucil [305-03-3]; Down 200; 13.2uM; PC3; HT_HG-U133A	PPP2R5B PER1 ARHGAP35 MAPK7 MAST2	8.22e-05	199	51	5	4523_DN
Drug	Estriol [50-27-1]; Down 200; 13.8uM; MCF7; HT_HG-U133A	SHANK2 NBEAL2 AMBRA1 IRS2 SMTN	8.22e-05	199	51	5	3563_DN
Drug	Iohexol [66108-95-0]; Up 200; 4.8uM; MCF7; HT_HG-U133A	PPP2R5B PRR36 AMBRA1 MAST2 PRRC2A	8.42e-05	200	51	5	3322_UP
Drug	SAR 020106	BRSK2 BRSK1	1.03e-04	7	51	2	ctd:C547874
Drug	thioridazine hydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A_EA	PRR36 PER1 IRS2 ZNF446	4.12e-04	156	51	4	1010_UP
Drug	Anisomycin [22862-76-6]; Up 200; 15uM; MCF7; HT_HG-U133A	SFPQ PER1 IRS2 EP300	4.76e-04	162	51	4	2658_UP
Drug	AICAR monophosphate	MLXIPL BRSK2 MAPK7 BRSK1	4.87e-04	163	51	4	CID000000200
Drug	Pimozide [2062-78-4]; Up 200; 8.6uM; MCF7; HT_HG-U133A	PPP2R5B PER1 IRS2 MAPK7	5.21e-04	166	51	4	6780_UP
Drug	Lanatoside C [17575-22-3]; Up 200; 4uM; HL60; HT_HG-U133A	SFPQ EP300 CRK SOS1	5.58e-04	169	51	4	2193_UP
Drug	felodipine; Up 200; 10uM; MCF7; HT_HG-U133A_EA	SFPQ PRR36 PER1 IRS2	5.70e-04	170	51	4	965_UP
Drug	actarit	KIAA0586 BSN	5.79e-04	16	51	2	CID000002018
Drug	Cephaeline dihydrochloride heptahydrate [6487-30-5]; Up 200; 6uM; MCF7; HT_HG-U133A	SFPQ PCLO PER1 RCOR3	5.83e-04	171	51	4	5247_UP
Drug	Parthenolide [20554-84-1]; Up 200; 16.2uM; PC3; HT_HG-U133A	PER1 IRS2 MAPK7 SOS1	6.09e-04	173	51	4	5105_UP
Drug	Isoflupredone acetate [338-98-7]; Up 200; 9.6uM; HL60; HT_HG-U133A	BICRA PER1 IRS2 MAST2	6.22e-04	174	51	4	1873_UP
Drug	Strophantine octahydrate [11018-89-6]; Up 200; 5.4uM; HL60; HT_HG-U133A	SFPQ SFSWAP PER1 CRK	6.22e-04	174	51	4	1302_UP
Drug	mono-(2-ethylhexyl)phthalate	BICRA NBEAL2 IRS2 MMP9 BRSK1 EP300 RXRB	6.26e-04	658	51	7	ctd:C016599
Drug	myricetin	IRS2 MMP9 EP300	6.38e-04	75	51	3	ctd:C040015
Drug	chlorfenapyr	MLXIPL SHANK2	6.55e-04	17	51	2	CID000091778
Drug	Budesonide [51333-22-3]; Up 200; 9.2uM; HL60; HG-U133A	BICRA PER1 AMBRA1 IRS2	6.78e-04	178	51	4	1716_UP
Drug	Withaferin A [5119-48-2]; Down 200; 1uM; PC3; HT_HG-U133A	SFPQ PER1 ARHGAP35 MAPK7	6.92e-04	179	51	4	4554_DN
Drug	Strophantine octahydrate [11018-89-6]; Up 200; 5.4uM; MCF7; HT_HG-U133A	SFPQ PER1 IRS2 ARHGAP35	6.92e-04	179	51	4	2656_UP
Drug	Methotrexate [59-05-2]; Down 200; 8.8uM; MCF7; HT_HG-U133A	SFPQ EIF5 IRS2 SMTN	7.21e-04	181	51	4	5419_DN
Drug	retinol palmitate	MMP9 EP300	7.36e-04	18	51	2	ctd:C014794
Drug	retinoic acid; Down 200; 1uM; MCF7; HT_HG-U133A_EA	PODXL EP300 CRK SMTN	7.83e-04	185	51	4	1049_DN
Drug	Methylprednisolone, 6-alpha [83-43-2]; Up 200; 10.6uM; HL60; HG-U133A	BICRA PER1 IRS2 MAST2	7.83e-04	185	51	4	1567_UP
Drug	Alclometasone dipropionate [667634-13-2]; Up 200; 7.6uM; HL60; HT_HG-U133A	SHANK2 BICRA PER1 ARHGAP35	7.83e-04	185	51	4	2532_UP
Drug	Metaraminol bitartrate [33402-03-8]; Up 200; 8.6uM; PC3; HT_HG-U133A	EIF5 PER1 ARHGAP35 MAST2	8.15e-04	187	51	4	7368_UP
Drug	Betulinic acid [472-15-1]; Up 200; 8.8uM; MCF7; HT_HG-U133A	NBEAL2 PER1 IRS2 SMTN	8.31e-04	188	51	4	3281_UP
Drug	wortmannin from Penicillium funiculosum; Up 200; 0.01uM; MCF7; HT_HG-U133A_EA	IRS2 ARHGAP35 MAPK7 ZNF446	8.31e-04	188	51	4	1023_UP
Drug	Triamcinolone [124-94-7]; Up 200; 10.2uM; HL60; HG-U133A	NBEAL2 PER1 RCOR3 IRS2	8.31e-04	188	51	4	1395_UP
Drug	Clioquinol [130-26-7]; Up 200; 13uM; HL60; HT_HG-U133A	MLXIPL SHANK2 PCLO MMP9	8.48e-04	189	51	4	3084_UP
Drug	Thioguanosine [85-31-4]; Down 200; 12.6uM; MCF7; HT_HG-U133A	BCORL1 EIF5 SMTN SOS1	8.64e-04	190	51	4	2619_DN
Drug	Bepridil hydrochloride [74764-40-2]; Up 200; 10uM; MCF7; HT_HG-U133A	SHANK2 PER1 IRS2 ARHGAP35	8.64e-04	190	51	4	2629_UP
Drug	CP-320650-01 [172079-28-6]; Up 200; 10uM; MCF7; HT_HG-U133A	PPP2R5B KIAA0586 IRS2 EP300	8.81e-04	191	51	4	3905_UP
Drug	17-AAG; Down 200; 1uM; PC3; HT_HG-U133A	PCLO KIAA0586 BCORL1 SMTN	8.81e-04	191	51	4	1225_DN
Drug	AEBSF	MAPK7 MMP9 CRK SOS1	8.81e-04	191	51	4	CID000001701
Drug	rottlerin; Down 200; 10uM; MCF7; HT_HG-U133A_EA	SFPQ MMP9 MAST2 SMTN	8.81e-04	191	51	4	941_DN
Drug	Meclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; PC3; HT_HG-U133A	PPP2R5B SFSWAP PCLO RFX7	8.99e-04	192	51	4	4268_DN
Drug	Cimetidine [51481-61-9]; Down 200; 15.8uM; MCF7; HT_HG-U133A	PPP2R5B BICRA IRS2 ARHGAP35	9.16e-04	193	51	4	1464_DN
Drug	Mebeverine hydrochloride [2753-45-9]; Up 200; 8.6uM; PC3; HT_HG-U133A	SHANK2 EIF5 ARHGAP35 MAST2	9.16e-04	193	51	4	7147_UP
Drug	MS-275; Down 200; 10uM; PC3; HT_HG-U133A	SFSWAP EP300 CRK SMTN	9.16e-04	193	51	4	7084_DN
Drug	Tolazamide [1156-19-0]; Up 200; 12.8uM; HL60; HT_HG-U133A	MLXIPL PPP2R5B MAPK7 SMTN	9.16e-04	193	51	4	2482_UP
Drug	Clotrimazole [23593-75-1]; Down 200; 11.6uM; HL60; HG-U133A	SFPQ KIAA0586 BCORL1 EIF5	9.16e-04	193	51	4	1549_DN
Drug	Oxymetazoline hydrochloride [2315-02-8]; Down 200; 13.4uM; PC3; HT_HG-U133A	NBEAL2 PER1 AMBRA1 ARHGAP35	9.16e-04	193	51	4	2114_DN
Drug	Quercetine dihydrate [6151-25-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A	PRR36 KIAA0586 EIF5 SOS1	9.16e-04	193	51	4	4846_DN
Drug	Spironolactone [52-01-7]; Down 200; 9.6uM; HL60; HG-U133A	SFPQ BCORL1 AMBRA1 RFX7	9.16e-04	193	51	4	1380_DN
Drug	prochlorperazine dimaleate salt; Up 200; 10uM; MCF7; HG-U133A	AMBRA1 IRS2 RFX7 ZNF446	9.16e-04	193	51	4	455_UP
Drug	Azaguanine-8 [134-58-7]; Down 200; 26.2uM; MCF7; HT_HG-U133A	EP400 KIAA0586 MAST2 SMTN	9.34e-04	194	51	4	1670_DN
Drug	Fusaric acid [536-69-6]; Up 200; 22.4uM; MCF7; HT_HG-U133A	PPP2R5B SHANK2 PRR36 MAPK7	9.34e-04	194	51	4	3245_UP
Drug	Oxybutynin chloride [1508-65-2]; Down 200; 10.2uM; MCF7; HT_HG-U133A	PER1 AMBRA1 MAST2 ZNF446	9.34e-04	194	51	4	3168_DN
Drug	Capsaicin [404-86-4]; Down 200; 13uM; PC3; HT_HG-U133A	AMBRA1 ARHGAP35 CRK SOS1	9.34e-04	194	51	4	4612_DN
Drug	Clofilium tosylate [92953-10-1]; Down 200; 7.8uM; PC3; HT_HG-U133A	PPP2R5B NBEAL2 ARHGAP35 MAPK7	9.34e-04	194	51	4	4492_DN
Drug	Acetylsalicylsalicylic acid [530-75-6]; Down 200; 13.4uM; HL60; HG-U133A	BCORL1 PER1 AMBRA1 CRK	9.34e-04	194	51	4	1377_DN
Drug	DL-PPMP; Down 200; 2uM; MCF7; HT_HG-U133A_EA	SFPQ PODXL RCOR3 CCDC6	9.52e-04	195	51	4	1121_DN
Drug	Mycophenolic acid [24280-93-1]; Down 200; 12.4uM; PC3; HT_HG-U133A	SHANK2 BICRA ARHGAP35 MAST2	9.52e-04	195	51	4	4019_DN
Drug	Methyl benzethonium chloride [25155-18-4]; Down 200; 8.6uM; MCF7; HT_HG-U133A	SHANK2 PRR36 PCLO MAPK7	9.52e-04	195	51	4	3850_DN
Drug	Oxethazaine [126-27-2]; Up 200; 8.6uM; HL60; HG-U133A	BICRA KIAA0586 AMBRA1 MAST2	9.52e-04	195	51	4	1984_UP
Drug	Acyclovir [59277-89-3]; Up 200; 17.8uM; PC3; HG-U133A	PODXL BCORL1 PER1 AMBRA1	9.52e-04	195	51	4	1960_UP
Drug	Nifenazone [2139-47-1]; Down 200; 13uM; PC3; HT_HG-U133A	NBEAL2 PER1 MAPK7 PRRC2A	9.52e-04	195	51	4	2122_DN
Drug	0198306-0000 [212631-61-3]; Down 200; 10uM; PC3; HT_HG-U133A	PPP2R5B NBEAL2 CRK SOS1	9.52e-04	195	51	4	7102_DN
Drug	Flumethasone [2135-17-3]; Up 200; 9.8uM; PC3; HT_HG-U133A	MLXIPL PRR36 PER1 IRS2	9.52e-04	195	51	4	3712_UP
Disease	serine/threonine-protein kinase BRSK2 measurement	BRSK2 BRSK1	8.78e-06	3	51	2	EFO_0803063
Disease	cardiomyopathy (is_marker_for)	MMP9 EP300	6.12e-05	7	51	2	DOID:0050700 (is_marker_for)
Disease	Malignant neoplasm of breast	ARID1B KMT2D BCORL1 EIF5 PER1 MMP9 PRRC2A EP300 RXRB	8.33e-05	1074	51	9	C0006142
Disease	prostate cancer (is_marker_for)	KMT2D MAPK7 EP300 SOS1	1.55e-04	156	51	4	DOID:10283 (is_marker_for)
Disease	intracranial aneurysm (is_implicated_in)	KMT2D MMP9	1.91e-04	12	51	2	DOID:10941 (is_implicated_in)
Disease	T-Cell Lymphoma	KMT2D EP300	3.46e-04	16	51	2	C0079772
Disease	Abnormal behavior	BCORL1 BRSK2	3.46e-04	16	51	2	C0233514
Disease	ovulation	CCDC200 PRRC2A	4.92e-04	19	51	2	GO_0030728
Disease	HIV-1 infection, Susceptibility to viral and mycobacterial infections	PODXL BICRA	6.02e-04	21	51	2	EFO_0000180, Orphanet_391311
Disease	red blood cell density measurement	ARID1B EP400 PODXL IRS2 TEX9 RFX7 MAST2	7.56e-04	880	51	7	EFO_0007978
Disease	Retinal Diseases	TREX1 MMP9	1.00e-03	27	51	2	C0035309
Disease	irritable bowel syndrome	PCLO PRRC2A EP300	1.52e-03	131	51	3	EFO_0000555
Disease	brain ischemia (implicated_via_orthology)	MMP9 SOS1	1.68e-03	35	51	2	DOID:2316 (implicated_via_orthology)
Disease	hematocrit	ARID1B MIDN BCORL1 IRS2 BSN TEX9 MAST2	1.69e-03	1011	51	7	EFO_0004348
Disease	Liver carcinoma	MLXIPL ARID1B VASN IRS2 MMP9	1.80e-03	507	51	5	C2239176
Disease	Bladder Neoplasm	KMT2D MMP9 EP300	1.84e-03	140	51	3	C0005695
Disease	Malignant neoplasm of urinary bladder	KMT2D MMP9 EP300	1.88e-03	141	51	3	C0005684
Disease	Neoplasm of uncertain or unknown behavior of breast	ARID1B EP300	2.30e-03	41	51	2	C0496956
Disease	Breast adenocarcinoma	ARID1B EP300	2.30e-03	41	51	2	C0858252
Disease	Breast Carcinoma	ARID1B KMT2D MMP9 EP300 RXRB	2.33e-03	538	51	5	C0678222
Disease	bipolar disorder	KMT2D SHANK2 PODXL BICRA PCLO	3.15e-03	577	51	5	MONDO_0004985
Disease	susceptibility to childhood ear infection measurement	BRSK2 PPP1R11 BSN	3.25e-03	171	51	3	EFO_0007904

Protein segments in the cluster

Peptide	Gene	Start	Entry
PTSPSSPGLSPVPPP	PPP2R5B	11	Q15173
TPPTPPQTAQPPLPG	EP300	1906	Q09472
PPPPTSPSRTAVPPG	EP400	316	Q96L91
TNPAPPPSTGPPSSI	ARID3C	396	A6NKF2
PMPTPTPSSGPPSTP	BCORL1	356	Q5H9F3
TVPTSQVTGPPPQPP	ARID1B	1656	Q8NFD5
PTPPPSPNTQTPVQP	CCDC6	426	Q16204
TVQDSATPSPPPPPP	AMBRA1	261	Q9C0C7
QHTPPLPSTPTGPPP	C3orf36	91	Q3SXR2
VPPSPAQPPPGVSPS	CRK	71	P46108
LGPSPPAPSSTPTPT	RCOR3	391	Q9P2K3
PAPTPTPTPVQPTSP	MAPK7	591	Q13164
TPTPVQPTSPPPGPV	MAPK7	596	Q13164
PRPPTTTTPQPTAPP	MMP9	451	P14780
TPPLLPSSPSPSPSP	PODXL	16	O00592
PAGTPNPTPPSSPSV	BRSK2	456	Q8IWQ3
GEPTPLPPPTSQQPP	BSN	526	Q9UPA5
PVPPSTPWPTPPATT	PER1	861	O15534
PPVQPPGTTKPPAQP	PCLO	351	Q9Y6V0
PSSGMPSSPVPTPPP	TEPSIN	406	Q96N21
PTQMPPVPSPSQPPS	DLST	181	P36957
TPTTPPQPPDPSQPP	PPP1R11	106	O60927
PSASPSSSLQPPPPP	IRS2	1021	Q9Y4H2
GSVSSSETPPPPPPP	EIF5	171	P55010
PSVQPPSQPPPQPST	CCDC200	81	A0A1B0GVQ3
CPVPSTPPTPSPSTP	IGHA1	101	P01876
TPPTPSPSTPPTPSP	IGHA1	106	P01876
ASPTGTPGTTPPPSP	BRSK1	526	Q8TDC3
SPPPPTASPQRSPSP	MAST2	1351	Q6P0Q8
PSPRGTPPSPTPANP	B3GNT8	36	Q7Z7M8
PPSQGPHKSPTPPPT	BICRA	911	Q9NZM4
VPPVPTSPSPASPSP	MIDN	201	Q504T8
PGVTTTAPPPPGTTP	SFSWAP	406	Q12872
SPPPSSPESPTSPKP	NBEAL2	1301	Q6ZNJ1
PPASPPVSPSATPPS	PRR36	901	Q9H6K5
SAPPTPVPPSPPQPV	PRRC2A	671	P48634
PCSPSGQQPPSPPSP	SCRIB	1296	Q14160
NSPSPFTPPPPQTPS	SOS1	1251	Q07889
PPTPQSVPSPAPTPF	MLXIPL	456	Q9NP71
PVTSQPSPPQSPPPT	ARHGAP35	1466	Q9NRY4
SSPNPLPQGVPPPSP	RXRB	86	P28702
PQSVPPSPPPPSPTT	SHANK2	891	Q9UPX8
PPTPPSSGVPTTPPQ	SFPQ	166	P23246
PESPVTPSTPGSPPV	RELL1	146	Q8IUW5
TPSTPGSPPVSPGPL	RELL1	151	Q8IUW5
PTPTPTPTPTPTPTP	RFX7	851	Q2KHR2
SPPSTAPPTVGPVPQ	VASN	391	Q6EMK4
PGTPPVPTQPTPAET	ZNF446	306	Q9NWS9
SPPTSQGPPPTVPPP	TREX1	46	Q9NSU2
PSSQPPPPTPTLTPT	TRNP1	31	Q6NT89
PPPTPTLTPTPTPGQ	TRNP1	36	Q6NT89
TLTPTPTPGQSPPLP	TRNP1	41	Q6NT89
TPFPPPVQQPSTPGP	TEX9	16	Q8N6V9
PGSPEPPPSPPKTTS	SMTN	231	P53814
PTPQPTPPCSPSSPA	KIAA0586	1041	Q9BVV6
LSNPPTPPSSLPPTP	KMT2D	4616	O14686
TPPSSLPPTPPPSVQ	KMT2D	4621	O14686